drugset / Trial / NCT02170064

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

NCT02170064

Phase 2 Completed 35 enrolled Bial - Portela C S.A.
Parallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.

Timeline

Start
2005-06
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 30 mg/kg Oral

Indications